JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the District Court case has been settled on terms that are confidential allowing Teva by license to enter the U.S. market with its generic versions of Avandia® (Rosiglitazone Maleate), Avandamet® (Rosiglitazone Maleate/Metformin HCl) and Avandaryl® (Rosiglitazone Maleate/Glimepiride) oral tablets late in the first quarter, 2012.
